1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004.
2. Younossi ZM, Golabi P, Paik J, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061-1070. doi: 10.1111/liv.15852.
3. Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 2021;3(5):100322. doi: 10.1016/j.jhepr.2021.100322.
4. Pugliese N, Plaz Torres MC, Petta S, Valenti L, Giannini EG, Aghemo A. Is there an ‘ideal’ diet for patients with NAFLD? Eur J Clin Investig. 2022;52(3):e13659. doi: 10.1111/eci.13659.
5. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063–72. DOI: 10.1056/NEJMra1503519
6. Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3:e00112. DOI: 10.1002/edm2.112
7. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–64. DOI: 10.1016/j.cell.2021.04.015
8. Friedman SL, Neuschwander-TetriBA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908–22. DOI: 10.1038/s41591-018-0104-9
9. Angulo P, Machado MV, Diehl AM. Fibrosis in nonalcoholic fatty liver disease: Mechanisms and clinical implications. Semin Liver Dis. 2015;35:132–45. DOI: 10.1055/s-0035-1550065
10. Bruinstroop E, Zhou J, Tripathi M, et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. Mol Metab. 2021;53:101266. DOI: 10.1016/j. molmet.2021.101266
11. Zhou J, Tripathi M, Ho JP, et al. Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis. Thyroid. 2022;32:725–38. DOI: 10.1089/thy.2021.0621
12. Bohinc BN, Michelotti G, Xie G, et al. Repair-related Activation of Hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. Endocrinology. 2014;155:4591–601. DOI:10.1210/en.2014-1302
13. Ludwig U, Holzner D, Denzer C, et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: A cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr Disord. 2015;15:41. DOI: 10.1186/s12902-015-0030-5
14. Bano A, Chaker L, Plompen EPC, et al. Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam study. J Clin Endocrinol Metab. 2016;101:3204–11. DOI: 10.1210/jc.2016-1300
15. Mantovani A, Nascimbeni F, Lonardo A, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Thyroid. 2018;28:1270–84. DOI: 10.1089/thy.2018.0257
16. Bruinstroop E, Dalan R, Cao Y, et al. Low-dose Levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD. J Clin Endocrinol Metab. 2018;103:2698–706. DOI: 10.1210/jc.2018-00475
17. Zhou J, Tripathi M, Ho JP, et al. Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary mouse model of nonalcoholic steatohepatitis. Thyroid. 2022;32:725–38. DOI: 10.1089/thy.2021.0621
18. Chaves C, Bruinstroop E, Refetoff S, et al. Increased hepatic fat content in patients with resistance to thyroid hormone beta. Thyroid. 2021;31:1127–34. DOI: 10.1089/thy.2020.0651
19. Gres Karim, Meena Bansal. Resmetirom: An Orally Administered Small Molecule, Liver-directed, ß-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. touchREVIEWS in Endocrinology. 2023;19(1):60–70. Doi: https://doi.org/10.17925/EE.2023.19.1.60
20. Petta S, Targher G, Romeo S et al. The first MASH drug therapy on the horizon: Current perspective of resmetirom. Liver International. 2024;00:1–11. DOI: 10.1111.liv.15930.
21. Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4(5-isopropyl-6-oxo-1, 6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitirile (MGL-3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia. J Med Chem.2014;57(10):3912-3923. PubMed PMID: 24712661.
22. Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology.2014;146(3):726-35. PubMed PMID:24316260.
23. Alkhouri N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis:rationale for the development of resmetirom (MGL-3196). Expert Opinion on Ivestigational Drugs.2020;29(2):99-101. https://doi.org/10.1080/13543784.2020.1708899.
24. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213): 2012-2024. doi: 10.1016/S0140-6736(19)32517-6
25. Harrison SA, Bashir M, Moussa SE, et al. Effects of Resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun. 2021;5(4):573-588. doi: 10.1002/hep4.1657.
26. Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic fat reduction due to Resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol. 2022;20(6):1354-1361.e7. DOI: 10.1016/ j.cgh.2021.07.039
27. Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919-2928. doi: 10.1038/s41591-023-02603-1.
28. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497-509. doi: 10.1056/NEJMoa2309000
Facebook 
Masuk dengan Email
